Phase 2 N=12 An Open Label Trial of Bupropion and Naltrexone for Binge Drinking
Binge Drinking
Primary: Number of Participants With Treatment-Associated Adverse Events — 5; 2; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
Diabetes · Metabolic Syndrome x
Primary: Fasting Insulin — 15.4; 19.1; 20.2 μIU/mL
Phase 2 N=63 Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Malaria
Primary: Number of Subjects With Plasmodium Falciparum Parasitemia Defined by a Positive Blood Slide, Following Sporozoite Challenge — 4; 6; 12 Participants — p=<0.0001
Phase 2 N=296 Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression
Depression
Primary: Hamilton Rating Scale for Depression — 11.06; 12.52 units on a scale
Phase 2 N=49 Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
CD20+, B-cell Lymphomas · Mantle Cell Lymphoma · Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL)
Primary: Safety as Assessed by Avoidance of Grade 3-4 Adverse Events — 1 Participants
Phase 2 N=108 Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Psoriasis
Primary: Percentage of Participants Who Experienced Psoriasis Relapse (Treating Drop-Outs as Relapse) — 91.1; 87.0; 55.6; 30.4 percentage of participants — p=0.41
Phase 2 N=12 Vet-Harts Pilot Intervention for Veterans With Coronary Heart Disease
Heart Disease
Primary: SF-36v Physical Function Scale — -6.67; 13.33 units on a scale
Phase 2 N=254 Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Survival (OS) Time — 7.9; 10.3; 9.6 months
Phase 2 N=16 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
Hematologic Neoplasms · Multiple Myeloma · Anemia, Aplastic
Primary: Number of Participants With Presence of Donor Lymphohematopoietic Chimerism (Defined as at Least 50% Donor Cells in the Peripheral Blood) in Peripheral Blood by Day +100…
Phase 2 N=157 Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma · Metastatic Kidney Carcinoma · Stage III Renal Cell Cancer AJCC v7
Primary: Progression Free Survival (PFS) — 8.2; 5.6 Months — p=0.012
Phase 2 N=59 CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
Kidney Transplantation
Primary: Mean Cmax Pharmacokinetic Parameter- Part I — 66.3 ug/mL
Phase 2 N=60 Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
Diarrhea
Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events
Phase 2 N=21 Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
Hereditary Thyroid Gland Medullary Carcinoma · Locally Advanced Thyroid Gland Medullary Carcinoma · Multiple Endocrine Neoplasia Type 2A
Primary: Objective Response Rate of Sorafenib Tosylate in Metastatic Medullary Thyroid Carcinoma in Setting of Inherited Tumor Syndromes as Well as in Setting of Sporadic…
Phase 2 N=56 A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
Lymphoma, Non-Hodgkin
Primary: Safety: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 1; 0 Participants
Phase 2 N=184 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study
Onychomycosis
Primary: Number of Patients in Each Treatment Group With a Complete Therapeutic Cure — 1; 0; 1 Participants — p=0.4615